arXiv:2506.20587 · Journal of Chemical Theory and Computation
How to Use Quantum Computers for Biomolecular Free Energies
Jakob Günther, Thomas Weymuth, Moritz Bensberg, Freek Witteveen, Matthew S. Teynor, F. Emil Thomasen, Valentina Sora, William Bro‐Jørgensen, Raphael T. Husistein, Mihael Eraković, Marek Miller, Leah P. Weisburn, Minsik Cho, Marco Eckhoff, Aram W. Harrow, Anders Krogh, Troy Van Voorhis, Kresten Lindorff‐Larsen, Gemma C. Solomon, Markus Reiher, Matthias Christandl
Free energy calculations are at the heart of physics-based analyses of biochemical processes. They allow us to quantify molecular recognition mechanisms, which determine a wide range of biological phenomena, from how cells send and receive signals to how pharmaceutical compounds can be used to treat diseases. Quantitative and predictive free energy calculations require computational models that accurately capture both the varied and intricate electronic interactions between molecules as well as the entropic contributions from the motions of these molecules and their aqueous environment. However, accurate quantum-mechanical energies and forces can be obtained only for small atomistic models and not for large biomacromolecules. Here, we demonstrate how to consistently link accurate quantum-mechanical data obtained for substructures to the overall potential energy of biomolecular complexes using machine learning in an integrated algorithm. We do so using a two-fold quantum embedding strategy where the innermost quantum cores are treated at a very high level of accuracy. We demonstrate the viability of this approach for the molecular recognition of a ruthenium-based anticancer drug by its protein target by applying traditional quantum chemical methods. As such methods scale unfavorably with system size, we analyze the requirements for quantum computers to provide highly accurate energies that affect the resulting free energies. Once the requirements are met, our computational pipeline, FreeQuantum, is able to make efficient use of the quantum-computed energies, thereby enabling quantum computing-enhanced modeling of biochemical processes. This approach combines the exponential speedups of quantum computers for simulating interacting electrons with modern classical simulation techniques that incorporate machine learning to model large molecules.
Free energy calculations are at the heart of physics-based analyses of biochemical processes. They allow us to quantify molecular recognition mechanisms, which determine a wide range of biological phenomena, from how cells send and receive signals to how pharmaceutical compounds can be used to treat diseases. Quantitative and predictive free energy calculations require computational models that accurately capture both the varied and intricate electronic interactions between molecules as well as the entropic contributions from the motions of these molecules and their aqueous environment. However, accurate quantum-mechanical energies and forces can be obtained only for small atomistic models and not for large biomacromolecules. Here, we demonstrate how to consistently link accurate quantum-mechanical data obtained for substructures to the overall potential energy of biomolecular complexes using machine learning in an integrated algorithm. We do so using a two-fold quantum embedding strategy where the innermost quantum cores are treated at a very high level of accuracy. We demonstrate the viability of this approach for the molecular recognition of a ruthenium-based anticancer drug by its protein target by applying traditional quantum chemical methods. As such methods scale unfavorably with system size, we analyze the requirements for quantum computers to provide highly accurate energies that affect the resulting free energies. Once the requirements are met, our computational pipeline, FreeQuantum, is able to make efficient use of the quantum-computed energies, thereby enabling quantum computing-enhanced modeling of biochemical processes. This approach combines the exponential speedups of quantum computers for simulating interacting electrons with modern classical simulation techniques that incorporate machine learning to model large molecules.
Our understanding of the physics of biological molecules, such as proteins and DNA, is limited because the approximations we usually apply to model inert materials are not, in general, applicable to soft, chemically inhomogeneous systems. The configurational complexity of biomolecules means the entropic contribution to the free energy is a significant factor in their behaviour, requiring detailed dynamical calculations to fully evaluate. Computer simulations capable of taking all interatomic interactions into account are therefore vital. However, even with the best current supercomputing facilities, we are unable to capture enough of the most interesting aspects of their behaviour to properly understand how they work. This limits our ability to design new molecules, to treat diseases, for example. Progress in biomolecular simulation depends crucially on increasing the computing power available. Faster classical computers are in the pipeline, but these provide only incremental improvements. Quantum computing offers the possibility of performing huge numbers of calculations in parallel, when it becomes available. We discuss the current open questions in biomolecular simulation, how these might be addressed using quantum computation and speculate on the future importance of quantum-assisted biomolecular modelling.
Our understanding of the physics of biological molecules, such as proteins and DNA, is limited because the approximations we usually apply to model inert materials are not, in general, applicable to soft, chemically inhomogeneous systems. The configurational complexity of biomolecules means the entropic contribution to the free energy is a significant factor in their behaviour, requiring detailed dynamical calculations to fully evaluate. Computer simulations capable of taking all interatomic interactions into account are therefore vital. However, even with the best current supercomputing facilities, we are unable to capture enough of the most interesting aspects of their behaviour to properly understand how they work. This limits our ability to design new molecules, to treat diseases, for example. Progress in biomolecular simulation depends crucially on increasing the computing power available. Faster classical computers are in the pipeline, but these provide only incremental improvements. Quantum computing offers the possibility of performing huge numbers of calculations in parallel, when it becomes available. We discuss the current open questions in biomolecular simulation, how these might be addressed using quantum computation and speculate on the future importance of quantum-assisted biomolecular modelling.
The exorbitant costs, protracted timelines, and elevated attrition rates associated with traditional drug-discovery pipelines underscore the pressing necessity for computational frameworks that can elucidate biomolecular interactions with quantum-level precision and practical scalability. This study introduces a Hybrid Quantum Classical (HQC) framework that combines quantum variational algorithms, classical molecular dynamics, and quantum-assisted machine-learning optimization into a single drug-screening workflow. It builds on the basic idea of Quantum Molecular Simulation (QMS). In the suggested design, quantum processors are used to selectively fix high-fidelity electronic interactions in reactive binding sites, while classical engines model the large-scale conformational dynamics of biomolecular environments. An adaptive quantum-machine-learning layer speeds up convergence even more by learning how structure and energy are related from quantum-refined descriptors. Benchmark tests against oncogenic targets like EGFR, BCR-ABL1, and p53 show that our method is up to 27% more accurate at converging binding energy and takes 4.3 times less time to compute than standard density-functional-theory and standalone QMS methods. The HQC framework makes quantum drug simulation possible for real-world drug discovery by reducing the limitations of current quantum hardware while keeping electronic-scale accuracy. This study demonstrates that hybrid quantum-classical modeling is a scalable and hardware-compatible approach for advancing next-generation computational drug design and precision therapeutics.
The ability to perform ab initio molecular dynamics simulations using potential energies calculated on quantum computers would allow virtually exact dynamics for chemical and biochemical systems, with substantial impacts on the fields of catalysis and biophysics. However, noisy hardware, the costs of computing gradients, and the number of qubits required to simulate large systems present major challenges to realizing the potential of dynamical simulations using quantum hardware. Here, we demonstrate that some of these issues can be mitigated by recent advances in machine learning. By combining transfer learning with techniques for building machine-learned potential energy surfaces, we propose a new path forward for molecular dynamics simulations on quantum hardware. We use transfer learning to reduce the number of energy evaluations that use quantum hardware by first training models on larger, less accurate classical datasets and then refining them on smaller, more accurate quantum datasets. We demonstrate this approach by training machine learning models to predict a molecule's potential energy using Behler-Parrinello neural networks. When successfully trained, the model enables energy gradient predictions necessary for dynamics simulations that cannot be readily obtained directly from quantum hardware. To reduce the quantum resources needed, the model is initially trained with data derived from low-cost techniques, such as Density Functional Theory, and subsequently refined with a smaller dataset obtained from the optimization of the Unitary Coupled Cluster ansatz. We show that this approach significantly reduces the size of the quantum training dataset while capturing the high accuracies needed for quantum chemistry simulations.
This paper explores the potential of integrating quantum computing with bioinformatics to revolutionize protein structure prediction. Traditional methods face significant computational challenges, particularly with complex proteins. We propose a novel approach leveraging quantum algorithms to accelerate molecular simulations and integrate biological data for enhanced prediction accuracy. The core claim centers on the ability to achieve more precise protein structure determination through this combined methodology. Specifically, we outline a mechanism utilizing quantum algorithms to drastically reduce simulation times and subsequently, incorporate biological information for optimization. This represents a new paradigm in protein structure prediction, offering a pathway to accurately model protein folding and dynamics. The work delves into the theoretical foundations and potential algorithmic implementations, laying the groundwork for future research and development in this exciting field. The focus is on the computational speedup offered by quantum approaches and the strategic integration with existing bioinformatics techniques.
Early-stage decisions in the pharmaceutical development process carry outsized consequences for eventual clinical success, yet the computational tools underpinning these decisions remain fundamentally constrained. Computer-aided drug design (CADD) has transformed how researchers navigate chemical space and predict ligand–target interactions, but classical implementations rely on mechanical force-field approximations that fail to capture polarisation, charge transfer, and electron correlation effects central to molecular recognition and reactivity. Quantum-mechanical treatments that correctly describe these phenomena scale exponentially with system size on classical hardware, rendering them impractical for drug-relevant biomolecules. Quantum computing offers a physically motivated path beyond this scaling barrier: by exploiting superposition, entanglement, and interference, quantum algorithms can in principle simulate electronic structure with polynomial resource requirements for targeted problem classes. This article provides a theoretical review of how quantum computation integrates throughout the drug discovery pipeline, from target identification to lead optimisation. Its primary contribution is a pipeline-level mapping of quantum methods—including the Variational Quantum Eigensolver (VQE), quantum machine learning, and quantum-enhanced optimisation—to specific drug development stages. The review critically distinguishes near-term NISQ (Noisy Intermediate-Scale Quantum: current devices with 50–1,000 noisy qubits operating without full error correction) capabilities from fault-tolerant quantum computing (FTQC) requirements, quantifies current resource gaps through a worked CYP3A4 case study, and identifies algorithmic limitations (barren plateaus, ansatz expressibility, measurement overhead), hardware scalability, and error correction overhead as the principal barriers to practical deployment.